Royalty Pharma plc
RPRX
$31.79
$0.511.63%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -61.72% | 433.30% | 2,034.87% | -99.03% | 585.50% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -0.79% | 17.31% | 4.83% | -10.16% | -3.39% |
| Total Other Non-Cash Items | 51.51% | -268.63% | -179.95% | 88.51% | -199.47% |
| Change in Net Operating Assets | 7.26% | 7.43% | 0.56% | -10.04% | 18.58% |
| Cash from Operations | 5.53% | 6.90% | -0.97% | -13.98% | 34.72% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 57.61% | -33.53% | -930.79% | 91.34% | -121.94% |
| Cash from Investing | 57.61% | -33.53% | -930.79% | 91.34% | -121.94% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 65.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 45.79% | -21.31% | -- | -- | 78.45% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.43% | 0.93% | -1.21% | -5.00% | 0.46% |
| Other Financing Activities | 16.89% | 3.78% | -18.18% | -5.20% | 13.32% |
| Cash from Financing | 20.75% | -128.14% | 645.58% | 8.58% | 82.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 97.42% | -188.38% | 151.82% | 179.66% | 62.85% |
